S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
Is This The End of Capitalism? (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
Is This The End of Capitalism? (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
Is This The End of Capitalism? (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
Is This The End of Capitalism? (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
NASDAQ:TXG

10x Genomics - TXG Stock Forecast, Price & News

$48.65
+0.62 (+1.29%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$46.94
$48.78
50-Day Range
$31.68
$48.65
52-Week Range
$23.81
$100.00
Volume
696,676 shs
Average Volume
1.14 million shs
Market Capitalization
$5.57 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.00

10x Genomics MarketRank™ Forecast

Analyst Rating
Hold
2.44 Rating Score
Upside/​Downside
4.8% Upside
$51.00 Price Target
Short Interest
Healthy
7.24% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.90
Upright™ Environmental Score
News Sentiment
1.19mentions of 10x Genomics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$227,008 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.60) to ($1.23) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

776th out of 1,055 stocks

Analytical Instruments Industry

23rd out of 28 stocks


TXG stock logo

About 10x Genomics (NASDAQ:TXG) Stock

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Receive TXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter.

TXG Stock News Headlines

TXG.O - | Stock Price & Latest News | Reuters
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
10x Genomics Reports Third Quarter 2022 Financial Results
10x Genomics to Host Investor Day on December 8, 2022
A Strong Dollar Could Whack These Biotech Stocks
See More Headlines
Receive TXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter.

TXG Company Calendar

Last Earnings
11/02/2022
Today
1/28/2023
Next Earnings (Confirmed)
2/15/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TXG
Fax
N/A
Employees
1,239
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$51.00
High Stock Price Forecast
$65.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+4.8%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
9 Analysts

Profitability

Net Income
$-58,220,000.00
Pretax Margin
-32.07%

Debt

Sales & Book Value

Annual Sales
$490.49 million
Book Value
$7.27 per share

Miscellaneous

Free Float
101,781,000
Market Cap
$5.57 billion
Optionable
Optionable
Beta
1.68

Key Executives

  • Dr. Serge Saxonov Ph.D. (Age 46)
    Co-Founder, CEO & Director
    Comp: $736.52k
  • Dr. Benjamin J. Hindson Ph.D.Dr. Benjamin J. Hindson Ph.D. (Age 48)
    Co-Founder, Pres, Chief Scientific Officer & Director
    Comp: $496k
  • Mr. Justin J. McAnearMr. Justin J. McAnear (Age 47)
    Chief Financial Officer
    Comp: $470.4k
  • Mr. Eric S. Whitaker Esq. (Age 56)
    Chief Legal Officer
    Comp: $505k
  • Mr. Michael Schnall-Levin
    Founding Scientist & CTO
  • Ms. Cassie Corneau
    Mang. of Investor Relations and Strategic Fin.
  • Mr. Jonathan Schimmel
    VP of Global Support & Sales Operations
  • Ms. Rebecca Port
    Chief People Officer
  • Ms. Ruth De Backer (Age 46)
    Chief Bus. Officer
  • Mr. Jim Wilbur Ph.D.
    Chief Commercial Officer













TXG Stock - Frequently Asked Questions

Should I buy or sell 10x Genomics stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last twelve months. There are currently 2 sell ratings, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TXG shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TXG, but not buy additional shares or sell existing shares.
View TXG analyst ratings
or view top-rated stocks.

What is 10x Genomics' stock price forecast for 2023?

9 equities research analysts have issued twelve-month target prices for 10x Genomics' stock. Their TXG share price forecasts range from $25.00 to $65.00. On average, they expect the company's stock price to reach $51.00 in the next twelve months. This suggests a possible upside of 4.8% from the stock's current price.
View analysts price targets for TXG
or view top-rated stocks among Wall Street analysts.

How have TXG shares performed in 2023?

10x Genomics' stock was trading at $36.44 at the beginning of 2023. Since then, TXG stock has increased by 33.5% and is now trading at $48.65.
View the best growth stocks for 2023 here
.

Are investors shorting 10x Genomics?

10x Genomics saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 6,200,000 shares, a decline of 16.9% from the December 31st total of 7,460,000 shares. Based on an average daily volume of 1,360,000 shares, the days-to-cover ratio is currently 4.6 days. Currently, 7.2% of the shares of the company are sold short.
View 10x Genomics' Short Interest
.

When is 10x Genomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 15th 2023.
View our TXG earnings forecast
.

How can I listen to 10x Genomics' earnings call?

10x Genomics will be holding an earnings conference call on Wednesday, February 15th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were 10x Genomics' earnings last quarter?

10x Genomics, Inc. (NASDAQ:TXG) issued its quarterly earnings data on Wednesday, November, 2nd. The company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.08. The company had revenue of $131.10 million for the quarter, compared to analyst estimates of $129.13 million. 10x Genomics had a negative trailing twelve-month return on equity of 21.01% and a negative net margin of 33.20%. The business's quarterly revenue was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.15) earnings per share.

What guidance has 10x Genomics issued on next quarter's earnings?

10x Genomics updated its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $500.00 million-$520.00 million, compared to the consensus revenue estimate of $509.87 million.

What is Serge Saxonov's approval rating as 10x Genomics' CEO?

25 employees have rated 10x Genomics Chief Executive Officer Serge Saxonov on Glassdoor.com. Serge Saxonov has an approval rating of 100% among the company's employees. This puts Serge Saxonov in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did 10x Genomics IPO?

(TXG) raised $297 million in an initial public offering (IPO) on Thursday, September 12th 2019. The company issued 9,000,000 shares at a price of $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Cowen was co-manager.

What is 10x Genomics' stock symbol?

10x Genomics trades on the NASDAQ under the ticker symbol "TXG."

Who are 10x Genomics' major shareholders?

10x Genomics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (7.52%), ARK Investment Management LLC (3.77%), Financial Consulate Inc. (0.14%), Nordwand Advisors LLC (0.12%), Allworth Financial LP (0.02%) and Capricorn Fund Managers Ltd (0.01%). Insiders that own company stock include Associates Vi LP Venrock, Benjamin J Hindson, Benjamin J Hindson, Bradford Crutchfield, Bryan E Roberts, Foresite Capital Management I,, John R Stuelpnagel, John R Stuelpnagel, Justin J Mcanear, Justin J Mcanear, Serge Saxonov and Sridhar Kosaraju.
View institutional ownership trends
.

How do I buy shares of 10x Genomics?

Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 10x Genomics' stock price today?

One share of TXG stock can currently be purchased for approximately $48.65.

How much money does 10x Genomics make?

10x Genomics (NASDAQ:TXG) has a market capitalization of $5.57 billion and generates $490.49 million in revenue each year. The company earns $-58,220,000.00 in net income (profit) each year or ($1.48) on an earnings per share basis.

How many employees does 10x Genomics have?

The company employs 1,239 workers across the globe.

How can I contact 10x Genomics?

10x Genomics' mailing address is 6230 STONERIDGE MALL ROAD, PLEASANTON CA, 94588. The official website for the company is www.10xgenomics.com. The company can be reached via phone at 925-401-7300 or via email at investors@10xgenomics.com.

This page (NASDAQ:TXG) was last updated on 1/28/2023 by MarketBeat.com Staff